IRVINE, Calif., Nov. 12 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals,
Inc. (Nasdaq: ISTA), presented today results from the Company's two Phase
III clinical trials of Xibrom(TM) (bromfenac sodium ophthalmic solution) QD
(once- daily) formulation, a new formulation of ISTA's ocular,
non-steroidal anti- inflammatory agent. The multi-center studies evaluated
the new once-daily formulation of Xibrom versus placebo in over 500
patients who underwent cataract surgery. The highly statistically
significant findings demonstrated Xibrom QD (once-daily) was superior to
placebo (P less than or equal to 0.0001) in achieving both the primary
efficacy endpoint of absence of ocular inflammation 15 days following
surgery and the secondary efficacy endpoint of elimination of ocular pain
at day one. In addition, compared to placebo, bromfenac produced a lower
overall incidence of ocular adverse events. William B. Trattler, M.D.
presented the results during the 2007 Annual Meeting of the American
Academy of Ophthalmology (AAO) being held in New Orleans, Louisiana.

ISTA also announced today a second poster presentation at the AAO
meeting. This study demonstrated the currently marketed twice-daily
formulation of Xibrom was as effective as both diclofenac sodium 0.1%
ophthalmic solution or ketorolac tromethamine 0.5% ophthalmic solution,
each dosed four times daily, when used for 3 months in the treatment of
cystoid macular edema (CME) following uncomplicated cataract surgery.

A total of 542 patients were enrolled in two randomized, double-masked,
placebo-controlled studies under the same protocol at 39 sites in the U.S.
Subjects were assigned randomly to receive either Xibrom once-daily or
placebo (n=360) or (n=182). Dosing began one day before cataract surgery
and continued through post-surgery day 14. Elimination of ocular pain was
assessed at Day 1 and complete absence of ocular inflammation was assessed
on Day 15.

In this study, 122 patients with acute CME within 1 year after
uncomplicated cataract surgery were treated for 3 months as follows:
approximately half of the patients with Xibrom twice daily, and 30 each
with either diclofenac or ketorolac four times daily. Visual acuity was
measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts.
While no significant difference in ETDRS letters gained was noted between
the three treatment groups, the patients treated with Xibrom recorded the
greatest gain in visual function.

Xibrom(TM) (bromfenac ophthalmic solution)

Xibrom is a topical non-steroidal anti-inflammatory compound for the
treatment of ocular inflammation and pain. Xibrom is the first and only
FDA-approved twice-daily NSAID for inflammation and pain following cataract
surgery. In 2006, Xibrom became the second highest-prescribed topical NSAID
by ophthalmologists on a dollar basis, according to IMS data. Xibrom, under
a different trade name but identical formulation, was launched in Japan in
2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights
for Xibrom in 2002 and launched the product in the U.S. in 2005.

About ISTA

ISTA Pharmaceuticals is an ophthalmic pharmaceutical company. ISTA's
products and product candidates addressing the $3.2 billion U.S.
prescription ophthalmic industry include therapies for inflammation, ocular
pain, glaucoma, allergy, and dry eye. The Company currently markets three
products and is developing a strong product pipeline to fuel future growth
and market share. The Company's product development and commercialization
strategy is to launch a new product every 12 to 18 months, thereby
continuing its growth to become the leading niche ophthalmic pharmaceutical
company in the U.S. For additional information regarding ISTA, please visit
ISTA Pharmaceuticals' website at http://www.istavision.com.

Forward-Looking Statements

Any statements contained in this press release referring to future
events or other non-historical matters are forward-looking statements.
Without limiting the foregoing, but by way of example, statements contained
in this press release concerning prospects related to the projected
timelines for filing of a supplemental New Drug Application for Xibrom QD
(once-daily) with the Food and Drug Administration and the expected
approval of ISTA's application, the Company's expectation patients and
physicians will choose Xibrom QD (once-daily) over other ophthalmic NSAID
formulations, and ISTA's goals of bringing a new product to market every 12
to 18 months and becoming the leading niche ophthalmic pharmaceutical
company in the U.S., are forward-looking statements. Except as required by
law, ISTA disclaims any intent or obligation to update any forward-looking
statements. These forward- looking statements are based on ISTA's
expectations as of the date of this press release and are subject to risks
and uncertainties that could cause actual results to differ materially.
Important factors that could cause actual results to differ from current
expectations include, among others: the inherent uncertainty associated
with financial projections and estimates, timely and successful
implementation of ISTA's strategic initiatives; delays and uncertainties
related to ISTA's research and development programs (including without
limitation the difficulty of predicting the timing or outcome of
bepotastine product development efforts); the timing, scope, and outcome of
FDA or other regulatory agency approval or actions; uncertainties and risks
regarding market acceptance of and demand for ISTA's approved products; the
impact of competitive technologies, products, and pricing; uncertainties
and risks related to ISTA's ability to properly manage its growth;
uncertainties and risks related to the continued availability of
third-party sourced products and raw materials on commercially reasonable
terms, or at all; uncertainties and risks related to successful compliance
with FDA and/or other governmental regulations applicable to ISTA's
facilities, products, and/or business; uncertainties and risks related to
the scope, validity, and enforceability of patents related to ISTA's
products and technologies and the impact of patents and other intellectual
property rights held by third parties; and such other risks and
uncertainties as detailed from time to time in ISTA's public filings with
the U.S. Securities and Exchange Commission, including but not limited to
ISTA's Annual Report on Form 10-K for the year ended December 31, 2006 and
its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2007,
June 30, 2007 and September 30, 2007.

(Date:9/27/2017)... 27, 2017 Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...

(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...

(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...

(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...

(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand ... Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness will be ... Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection ...